RxDoctor Payments Data

Erica Cox

Family · Kernersville, NCNPI 1407015217

Payments from drug & device makers

$4,553in general payments, 2019–2025

Across 220 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$780
  • Lilly USA, LLC$696
  • AstraZeneca$664
  • Amgen$244
  • Novo Nordisk$231
  • AbbVie$181
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,45498%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,553 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,372
Medicare patients
127
Services billed
553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide66$88,517
JardianceEmpagliflozin61$76,550
EliquisApixaban59$58,259
FarxigaDapagliflozin Propanediol38$49,944
OzempicSemaglutide34$47,261
RybelsusSemaglutide19$34,163
JanuviaSitagliptin Phosphate27$25,668
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,835
Synjardy XrEmpagliflozin/Metformin Hcl16$21,306
MyrbetriqMirabegron15$19,784
VascepaIcosapent Ethyl14$13,763
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,258
GlyxambiEmpagliflozin/Linagliptin12$13,211
ConcertaMethylphenidate Hcl12$11,335
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$65$111,06789 claims
Lilly USA, LLCMounjaro$696$88,51766 claims
Novo NordiskOzempic, Rybelsus$231$81,42453 claims
AstraZenecaFarxiga, Breztri Aerosphere$664$63,20259 claims
PfizerEliquis, Paxlovid$780$61,11890 claims
MerckJanuvia$113$25,66827 claims
GSKTrelegy Ellipta$90$21,83525 claims
Astellas Pharma US IncMyrbetriq$31$19,78415 claims
Johnson & JohnsonConcerta$103$11,33512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Kernersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →